DH
Definitive Healthcare Corp. NASDAQ Listed Sep 15, 2021$0.92
Mkt Cap $96.3M
52w Low $0.90
0.5% of range
52w High $4.70
50d MA $1.10
200d MA $2.54
P/E (TTM)
-0.8x
EV/EBITDA
-2.0x
P/B
0.3x
Debt/Equity
0.6x
ROE
-70.9%
P/FCF
8.3x
RSI (14)
—
ATR (14)
—
Beta
1.60
50d MA
$1.10
200d MA
$2.54
Avg Volume
349.6K
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
550 Cochituate Road · Framingham, MA 01701 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | 0.03 | 0.06 | +100.0% | 0.92 | +13.9% | +3.3% | — | — | — | — | — |
| Feb 26, 2026 | AMC | 0.06 | 0.06 | +0.0% | 1.40 | -9.3% | -8.6% | -18.6% | -17.1% | -12.9% | -12.9% | — |
| Nov 6, 2025 | AMC | 0.06 | 0.07 | +16.7% | 2.65 | +6.0% | +10.6% | +7.5% | +8.3% | +2.6% | +2.6% | — |
| Aug 7, 2025 | AMC | 0.05 | 0.07 | +40.0% | 3.97 | +5.3% | -2.8% | -11.3% | -9.3% | -0.8% | -4.3% | — |
| May 8, 2025 | AMC | 0.02 | 0.05 | +150.0% | 2.81 | +27.8% | +31.3% | +27.4% | +28.1% | +21.4% | +18.1% | — |
| Feb 27, 2025 | AMC | 0.07 | 0.08 | +14.3% | 4.92 | -23.6% | -34.3% | -42.5% | -43.5% | -43.7% | -46.5% | — |
| Nov 7, 2024 | AMC | 0.08 | 0.10 | +25.0% | 4.31 | +2.1% | -1.6% | +2.1% | +6.0% | +4.9% | +3.5% | — |
| Aug 5, 2024 | AMC | 0.09 | 0.09 | +0.0% | 3.55 | +5.6% | +2.8% | +7.9% | +7.9% | +9.6% | +5.1% | — |
| May 7, 2024 | AMC | 0.08 | 0.08 | +0.0% | 7.25 | -37.1% | -26.2% | -28.7% | -26.6% | -25.1% | -24.8% | — |
| Feb 28, 2024 | AMC | 0.07 | 0.07 | +0.0% | 9.20 | +8.5% | +3.5% | -2.5% | -3.0% | -9.2% | -11.5% | — |
| Nov 2, 2023 | AMC | 0.06 | 0.09 | +50.0% | 6.06 | +10.1% | +20.0% | +23.6% | +21.8% | +22.9% | +14.4% | — |
| Aug 14, 2023 | AMC | 0.05 | 0.08 | +60.0% | 10.48 | -7.2% | -3.3% | -4.6% | -4.6% | -5.5% | -4.8% | — |
| May 4, 2023 | AMC | 0.05 | 0.06 | +20.0% | 9.90 | -4.4% | +3.1% | +1.7% | -1.5% | -0.9% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Barclays | Maintains | Underweight → Underweight | — | $1.05 | $1.08 | +2.9% | +10.5% | +17.1% | +3.8% | +2.9% | +4.8% |
| Feb 27 | Canaccord Genuity | Maintains | Hold → Hold | — | $1.40 | $1.27 | -9.3% | -8.6% | -18.6% | -17.1% | -12.9% | -12.9% |
| Feb 27 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $1.40 | $1.27 | -9.3% | -8.6% | -18.6% | -17.1% | -12.9% | -12.9% |
| Dec 9 | Barclays | Maintains | Underweight → Underweight | — | $2.45 | $2.45 | +0.0% | -3.3% | -2.9% | -6.1% | -5.7% | -6.1% |
| Nov 10 | Canaccord Genuity | Maintains | Hold → Hold | — | $2.93 | $2.97 | +1.4% | -2.7% | -2.0% | -7.2% | -7.2% | -6.5% |
| Aug 8 | Stifel | Maintains | Buy → Buy | — | $3.97 | $4.18 | +5.3% | -2.8% | -11.3% | -9.3% | -0.8% | -4.3% |
| May 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.69 | $3.83 | +3.8% | -3.0% | -2.4% | -7.6% | -10.0% | -11.1% |
| Mar 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.83 | $2.78 | -1.8% | -1.8% | -2.1% | -7.1% | +0.7% | +0.4% |
| Mar 3 | Barclays | Maintains | Underweight → Underweight | — | $3.23 | $3.23 | +0.0% | -12.4% | -13.9% | -14.2% | -18.6% | -11.8% |
| Jan 16 | Needham | Maintains | Hold → Hold | — | $3.98 | $3.98 | +0.0% | -0.8% | -1.0% | +10.8% | +18.3% | +22.4% |
| Jan 13 | Barclays | Downgrade | Equal Weight → Underweight | — | $4.22 | $4.02 | -4.7% | -6.9% | -7.1% | -5.7% | -6.4% | -6.6% |
| Aug 9 | Deutsche Bank | Maintains | Hold → Hold | — | $3.83 | $3.76 | -1.8% | +1.6% | -2.6% | +1.8% | -1.6% | +4.7% |
| Aug 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.65 | $3.66 | +0.3% | +4.9% | +4.9% | +6.6% | +2.2% | +6.8% |
| Aug 7 | Baird | Maintains | Neutral → Neutral | — | $3.65 | $3.66 | +0.3% | +4.9% | +4.9% | +6.6% | +2.2% | +6.8% |
| Aug 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.55 | $3.75 | +5.6% | +2.8% | +7.9% | +7.9% | +9.6% | +5.1% |
| Jul 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $5.74 | $4.74 | -17.4% | -32.1% | -31.2% | -35.5% | -38.2% | -36.4% |
| Jul 31 | JP Morgan | Downgrade | Neutral → Underweight | — | $5.74 | $4.74 | -17.4% | -32.1% | -31.2% | -35.5% | -38.2% | -36.4% |
| Jul 31 | Stifel | Maintains | Buy → Buy | — | $5.74 | $4.74 | -17.4% | -32.1% | -31.2% | -35.5% | -38.2% | -36.4% |
| Jul 31 | Baird | Maintains | Neutral → Neutral | — | $5.74 | $4.74 | -17.4% | -32.1% | -31.2% | -35.5% | -38.2% | -36.4% |
| May 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $5.35 | $5.33 | -0.4% | -3.4% | -0.6% | +1.5% | +1.9% | +4.1% |
| May 9 | Deutsche Bank | Maintains | Hold → Hold | — | $5.35 | $5.33 | -0.4% | -3.4% | -0.6% | +1.5% | +1.9% | +4.1% |
| May 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $7.25 | $4.56 | -37.1% | -26.2% | -28.7% | -26.6% | -25.1% | -24.8% |
| May 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $7.25 | $4.56 | -37.1% | -26.2% | -28.7% | -26.6% | -25.1% | -24.8% |
| May 8 | Stifel | Maintains | Buy → Buy | — | $7.25 | $4.56 | -37.1% | -26.2% | -28.7% | -26.6% | -25.1% | -24.8% |
| Mar 1 | Barclays | Maintains | Equal Weight → Equal Weight | — | $9.52 | $9.57 | +0.5% | -5.8% | -6.3% | -12.3% | -14.5% | -12.0% |
| Feb 29 | Canaccord Genuity | Maintains | Hold → Hold | — | $9.20 | $9.98 | +8.5% | +3.5% | -2.5% | -3.0% | -9.2% | -11.5% |
| Jan 17 | Stifel | Maintains | Buy → Buy | — | $9.19 | $7.76 | -15.6% | -6.5% | -10.2% | -5.3% | +1.1% | +0.5% |
| Jan 17 | Needham | Downgrade | Buy → Hold | — | $9.19 | $7.76 | -15.6% | -6.5% | -10.2% | -5.3% | +1.1% | +0.5% |
| Jan 5 | Canaccord Genuity | Downgrade | Buy → Hold | — | $8.83 | $8.23 | -6.8% | +1.9% | +6.9% | +6.0% | +2.8% | +6.5% |
| Nov 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.06 | $6.67 | +10.1% | +20.0% | +23.6% | +21.8% | +22.9% | +14.4% |
| Aug 16 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.13 | $10.02 | -1.1% | -1.3% | -1.3% | -2.3% | -1.5% | +0.2% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $10.48 | $9.73 | -7.2% | -3.3% | -4.6% | -4.6% | -5.5% | -4.8% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $10.48 | $9.73 | -7.2% | -3.3% | -4.6% | -4.6% | -5.5% | -4.8% |
| Aug 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.48 | $9.73 | -7.2% | -3.3% | -4.6% | -4.6% | -5.5% | -4.8% |
| Aug 15 | BofA Securities | Maintains | Neutral → Neutral | — | $10.48 | $9.73 | -7.2% | -3.3% | -4.6% | -4.6% | -5.5% | -4.8% |
| Aug 1 | Needham | Maintains | Buy → Buy | — | $11.83 | $11.82 | -0.1% | -4.1% | -3.3% | -7.4% | -4.4% | -4.1% |
| Jul 24 | Baird | Downgrade | Outperform → Neutral | — | $11.53 | $10.98 | -4.8% | -1.3% | -0.5% | +4.9% | -1.8% | +0.9% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $10.21 | $10.14 | -0.7% | -1.4% | -4.5% | -3.9% | -4.3% | -10.7% |
| May 5 | Needham | Maintains | Buy → Buy | — | $9.90 | $9.46 | -4.4% | +3.1% | +1.7% | -1.5% | -0.9% | -1.3% |
| May 5 | Credit Suisse | Maintains | Neutral → Neutral | — | $9.90 | $9.46 | -4.4% | +3.1% | +1.7% | -1.5% | -0.9% | -1.3% |
| May 5 | BofA Securities | Maintains | Neutral → Neutral | — | $9.90 | $9.46 | -4.4% | +3.1% | +1.7% | -1.5% | -0.9% | -1.3% |
| Apr 19 | William Blair | Maintains | Outperform → Outperform | — | $10.98 | $11.14 | +1.5% | +2.3% | +0.5% | +8.0% | +4.6% | -4.5% |
| Feb 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.27 | $11.28 | +0.1% | +1.3% | +1.6% | +5.4% | +9.1% | +5.1% |
| Feb 24 | Credit Suisse | Maintains | Neutral → Neutral | — | $12.10 | $11.10 | -8.3% | -0.7% | -6.9% | -5.6% | -5.4% | -1.8% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $12.10 | $11.10 | -8.3% | -0.7% | -6.9% | -5.6% | -5.4% | -1.8% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $10.59 | $10.52 | -0.7% | -1.7% | +8.9% | +13.5% | +17.4% | +13.1% |
| Nov 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.92 | $11.30 | +3.5% | +5.3% | -6.3% | -7.1% | +5.2% | +9.2% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.83 | $12.00 | -13.2% | -21.0% | -16.8% | -26.0% | -26.7% | -16.9% |
| Nov 4 | Credit Suisse | Maintains | Neutral → Neutral | — | $13.83 | $12.00 | -13.2% | -21.0% | -16.8% | -26.0% | -26.7% | -16.9% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $13.83 | $12.00 | -13.2% | -21.0% | -16.8% | -26.0% | -26.7% | -16.9% |
No insider trades available.
8-K · 2.02
!! High
Definitive Healthcare Corp. -- 8-K 2.02: Earnings Results
Definitive Healthcare reported quarterly earnings results showing its operational performance and financial condition, with details available in the attached press release for investor review.
May 7
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
DH's termination of a material agreement creates earnings uncertainty and potential revenue loss, making the stock riskier until management clarifies the agreement's financial impact and strategic implications.
Apr 9
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary contains only technical XBRL metadata about DH's SEC submission format rather than substantive business information or disclosures.
Apr 3
8-K
Definitive Healthcare Corp. -- 8-K Filing
Definitive Healthcare exceeded revenue guidance for Q4 and full-year 2025, demonstrating stronger-than-expected performance in healthcare data and analytics market.
Feb 26
Data updated apr 25, 2026 5:08am
· Source: massive.com